Production of blood stem cells from reprogrammed adult cells is notoriously difficult. It emerges that a supportive microenvironment may be crucial for their efficient generation. See Article p.312 ...

Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the close of its seed financing. The close brings total ...

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, according to a study published in Science Advances. Shana Kelley, Ph.D., ...